Dihydropyridines

BACKGROUND OF THE INVENTION
This invention relates to certain dihydropyridines, specifically to certain 1,4-dihydropyridines having a heterocyclic group in a side chain attached to the 2-position, which have utility as anti-ischaemic and antihypertensive agents.
The compounds of the invention reduce the movement of calcium into the cell and they are thus able to delay or prevent the cardiac contracture which is believed to be caused by an accumulation of intracellular calcium under ischaemic conditions. Excessive calcium influx during ischaemia can have a number of additional adverse effects which would further compromise the ischaemic myocardium. These include less efficient use of oxygen for ATP production, activation of mitochondrial fatty acid oxidation and possibly, promotion of cell necrosis. Thus the compounds are useful in the treatment or prevention of a variety of cardiac conditions, such as angina pectoris, cardiac arrythmias, heart attacks and cardiac hypertrophy. The compounds also have vasodilator activity since they can inhibit calcium influx in cells of vascular tissue and they are thus also useful as antihypertensive agents and for the treatment of coronary vasospasm.
SUMMARY OF THE INVENTION
Thus according to the invention there are provided dihydropyridines of the formula: ##STR2## and their pharmaceutically acceptable acid addition salts; wherein
R is an optionally substituted aryl or heteroaryl group;
R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl;
Y is --(CH.sub.2).sub.n -- where n is 2, 3 or 4 and is optionally substituted by 1 or 2 methyl groups; and
R.sup.3 is an optionally substituted 5- or 6-membered heterocyclic group attached to the adjacent nitrogen atom by a carbon atom, said heterocyclic group being optionally fused to a further 5- or 6-membered heterocyclic group or to a benzene ring, said further heterocyclic group and benzene ring also being optionally substituted.
The pharmaceutically acceptable acid addition salts of the compounds of the formula (I) are those formed from acids which form non-toxic acid addition salts, for example the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or acid phosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate and tartrate salts.
The term "aryl" as used in this specification includes unsubstituted phenyl and phenyl substituted by, for example, one or two substituents each independently selected from nitro, halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, trifluoromethyl, and cyano. It also includes 1- and 2-naphthyl.
"Halo" means F, Cl, Br or I.
The term "heteroaryl" as used in this specification for R means an aromatic heterocyclic group which may optionally be substituted and includes, for example, benzofuranyl; benzothienyl; pyridyl optionally monosubstituted by methyl or cyano; quinolyl; benzoxazolyl; benthiazolyl; furyl; pyrimidinyl; thiazolyl; 2,1,3-benzoxadiazol-4-yl; 2,1,3-benzthiadiazol-4-yl; and thienyl optionally monosubstituted by halo or C.sub.1 -C.sub.4 alkyl.
Alkyl and alkoxy groups having 3 or more carbon atoms can be straight or branched chain.
R is preferably phenyl substituted by 1 or 2 substituents selected from halo and CF.sub.3. R is more preferably 2-chlorophenyl, 2,3-dichlorophenyl or 2-chloro-3-trifluoromethylphenyl. R is most preferably 2,3-dichlorophenyl.
Preferably either R.sup.1 is CH.sub.3 and R.sup.2 is C.sub.2 H.sub.5 or R.sup.1 is C.sub.2 H.sub.5 and R.sup.2 is CH.sub.3. Most preferably, R.sup.1 is CH.sub.3 and R.sup.2 is C.sub.2 H.sub.5.
Y is preferably --(CH.sub.2).sub.2 --.
R.sup.3 is preferably a nitrogen-containing heterocyclic group.
R.sup.3 is more preferably either (a) a monocyclic 5- or 6-membered heterocycle containing at least one N atom and optionally one or two further heteroatoms or groups each independently selected from O, S, ##STR3## N, and ##STR4## and is optionally substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, hydroxy, oxo, cyano, 3-(C.sub.1 -C.sub.4 alkyl)ureido, phenyl, phenoxy, pyridyl, acetyl, (C.sub.1 -C.sub.4 alkoxy)carbonyl, --NR.sup.4 R.sup.5, --SO.sub.2 NR.sup.4 R.sup.5, or --CONR.sup.4 R.sup.5 where either R.sup.4 are R.sup.5 are each independently H or C.sub.1 -C.sub.4 alkyl or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached represent a saturated 5- or 6-membered heterocyclic group optionally containing a further heteroatom or group selected from O, S, NH, --N(C.sub.1 -C.sub.4 alkyl) and --N.CHO; or (b) a bicyclic group which is an optionally substituted monocyclic 5- or 6- membered heterocycle as defined in (a) fused to an imidazole or benzene ring, said benzene ring being optionally substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy or halo.
R.sup.3 is most preferably a heterocyclic group selected from triazolyl, oxadiazolyl, pyrimidinyl or a partially saturated derivative thereof, purinyl, quinazolinyl, imidazolyl, imidazolinyl, triazinyl, pyridyl, thiazolyl, thiazolinyl, benzthiazolyl, thiadiazolyl, pyrazinyl, quinoxalinyl and pyrrolinyl, and their N- and S-oxides, R.sup.3 being optionally substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, hydroxy, oxo, cyano, 3-methylureido, phenyl, phenoxy, pyridyl, acetyl, carbamoyl, N-methylcarbamoyl, (C.sub.1 -C.sub.4 alkoxy)carbonyl, --NR.sup.4 R.sup.5, or --SO.sub.2 NR.sup.4 R.sup.5, where either R.sup.4 and R.sup.5 are each independently H or C.sub.1 -C.sub.4 alkyl or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached form a piperidino, morpholino, 4-methylpiperazin-1-yl or 4-formylpiperazin-1-yl group.
1,2,4-Triazol-3-yl, 1,2,4-oxadiazol-3-yl, 1,2,5-thiadiazol-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, imidazol-2-yl, 1,3,5-triazin-2-yl, pyrid-2-yl, thiazol-2-yl, pyrazin-2-yl and pyrrolin-2-yl, optionally substituted as above, represent typical instances of R.sup.3.
The most preferred individual heterocyclic groups represented by R.sup.3 are as follows: ##STR5##
In some of these groups tautomerism may occur, e.g. ##STR6## In such cases both tautomers are within the scope of this invention.
In the preferred individual compound, R is 2,3-dichlorophenyl, R.sup.1 is CH.sub.3, R.sup.2 is C.sub.2 H.sub.5, Y is --(CH.sub.2).sub.2 -- and R.sup.3 is ##STR7##
The compounds of the formula (I) containing one or more asymmetric centres will exist as one or more pairs of enantiomers, and such pairs or individual isomers may be separable by physical methods, e.g. by fractional crystallisation of the free bases or suitable salts or chromatography of the free bases. The invention includes the separated pairs as well as mixtures thereof, as racemic mixtures or as separated optically-active isomeric forms.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the invention can be prepared by a number of routes, including the following:
(1) The compounds of the formula (I) can be prepared via the following route: ##STR8##
Q is a facile leaving group, such as --NH.NO.sub.2, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkoxy, Cl, Br or I. Q is preferably methylthio, methoxy, ethoxy, chloro or nitroamino.
The reaction is typically carried out by heating the reactants at 50.degree.-130.degree. C., e.g. under reflux, in a suitable organic solvent until the reaction is substantially complete. Typical organic solvents include methanol, ethanol, n-butanol, acetonitrile, dimethylformamide (DMF), methylene chloride, etc. When Q is C.sub.1 -C.sub.4 alkylthio, Cl, Br or I, the presence of a base such as triethylamine, sodium carbonate or 4-dimethylaminopyridine is preferred. The product (I) can then be isolated and purified conventionally.
The starting materials of the formula (II) are the subject matter of our European patent application publication No. 0089167. Some typical methods for their preparation are however described in the Preparations hereinafter.
As disclosed in the said patent application, a typical route to the intermediates (II) is as follows: ##STR9##
An alternative route to the intermediates (II) is as follows: ##STR10##
Preparations 16 and 17 describe particularly useful routes to 2,3-dichlorobenzaldehyde and 2-chloro-3-trifluoromethylbenzaldehyde.
(2) Compounds in which R.sup.3 is ##STR11## can be prepared as follows: ##STR12## X is --SCH.sub.3, --OCH.sub.3 or --O.Phenyl.
These reactions are typically carried out in a suitable organic solvent such as methanol, ethanol, acetonitrile or tetrahydrofuran, with heating if necessary at up to 130.degree. C. and preferably under reflux. Heating is preferred when ethanol is used as the solvent. The reaction is generally complete in about 4 hours. The desired product can then be isolated and purified conventionally.
The starting materials of the formula (III) can be prepared from compounds of the formula (II) [see route (1) above] as follows: ##STR13##
(3) Compounds in which R.sup.3 is ##STR14## can be prepared from the compounds of the formula (II) as follows: ##STR15##
The reaction is typically carried out by stirring the reactants together in a suitable organic solvent, e.g. methylene chloride, for a few hours, and again the product can then be isolated and purified conventionally. The presence of base in the reaction mixture, e.g. triethylamine, is preferred.
(4) Compounds in which R.sup.3 is ##STR16## can be prepared as follows: ##STR17##
The reaction is typically carried out by stirring the reactants together at room temperature in a suitable solvent, e.g. CHCl.sub.3 /CH.sub.3 OH, until the reaction is substantially complete. If necessary, the reaction mixture can be heated to accelerate the reaction. The product can be isolated conventionally.
The starting materials of the formula (IV) can be prepared from the compounds of the formula (II) as follows: ##STR18##
(5) Compounds in which R.sup.3 is ##STR19## can be prepared as follows: ##STR20##
The starting ethoxycarbonylthioureido derivatives can be prepared as follows: ##STR21##
(6) Compounds in which R.sup.3 is ##STR22## can be prepared by the reaction of the corresponding amino compound (R.sup.3 =H) with 5-acetyl-2-amino-oxazole in aqueous methanol, typically by heating for 24 hours or so. The reaction produces a mixture of two products having R.sup.3 as above. These can be separated by conventional chromatographic procedures.
(7) Some of the compounds of the formula (I) can be prepared from other compounds of the formula (I), e.g., those where R.sup.3 is a heterocyclic group substituted by an [C.sub.1 -C.sub.4 -alkyl]carbamoyl group can be prepared by the reaction of the corresponding compounds in which the heterocyclic group is substituted by (C.sub.1 -C.sub.4 alkoxy)carbonyl with a C.sub.1 -C.sub.4 alkylamine. Similarly, compounds in which R.sup.3 is substituted by --NH.sub.2 can be prepared by reacting the corresponding methoxy-substituted derivatives with ammonia, generally in ethanol, and compounds in which R.sup.3 is substituted by --NHCONH(C.sub.1 -C.sub.4 alkyl) by reaction of the corresponding amino-substituted compound with a C.sub.1 -C.sub.4 alkylisocyanate.
Compounds in which R.sup.3 is a heterocyclic group substituted by an amino or substituted amino group, or a cyclic amino group, e.g. morpholino, piperidino or N-methyl piperazino, can be prepared by heating the corresponding chloro-substituted compound with the appropriate amine.
Compounds in which R.sup.3 is pyrazinyl can be prepared by the reduction of the corresponding compound in which R.sup.3 is a pyrazine-N-oxide with sodium dithionate, e.g. by heating in aqueous ethanol.
(8) Acid addition salts can be prepared conventionally, e.g. by reacting a solution of the free base in a suitable organic solvent with a solution of the desired acid in a suitable solvent, and either recovering the salt by filtration when it precipitates from solution, or by evaporation of the solution to dryness.
The ability of the compounds to inhibit the movement of calcium into the cell is shown by their effectiveness in reducing the response of isolated heart tissue to an increase in calcium ion concentration in vitro. The test is performed by mounting spirally cut strips of rat aorta with one end fixed and the other attached to a force transducer. The tissue is immersed in a bath of physiological saline solution containing potassium ions at a concentration of 45 millimolar and no calcium. Calcium chloride is added to the bath with a pipette to give a final calcium ion concentration of 2 millimolar. The change in tension caused by the resulting contraction of the tissue is noted. The bath is drained and replaced with fresh saline solution and, after 45 minutes, the test is repeated with the particular compound under test present in the saline solution. The concentration of compound required to reduce the response by 50% (IC.sub.50) is recorded.
The antihypertensive activity of the compounds is also evaluated after oral administration by measuring the fall in blood pressure in spontaneously hypertensive rats or renally hypertensive dogs.
For administration to man in the curative or prophylactic treatment of cardiac conditions and hypertension, oral dosages of the compounds will be in the range of from 5-100 mg daily for an average adult patient (70 kg), typically 10-60 mg daily. Thus for a typical adult patient, individual tablets or capsules will generally contain from 5, 10 or 20 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. Dosages for intravenous administration will typically be within the range 1 to 10 mg per single dose as required. In practice the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosages ranges are merited, and such are within the scope of this invention.
For human use, the compounds of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic.
Thus in a further aspect the invention provides a pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable diluent or carrier.
The invention also includes a compound of the formula (I), or a pharmaceutically acceptable acid addition salt thereof, for use in medicine, in particular in the treatment of ischaemic heart disease, angina, or hypertension in a human being.
The invention also provides a method of protecting the heart from the deleterious effects of ischaemia, which comprises administering an effective amount of a compound of the formula (I) or pharmaceutically acceptable acid addition salt thereof, or pharmaceutical composition as defined above.
The invention also includes a method of treating hypertension which comprises administering an antihypertensive amount of a compound of the formula (I) or pharmaceutically acceptable acid addition salt thereof, or pharmaceutical composition as defined above.

The following Examples illustrate the invention. All temperatures are in .degree.C.:
EXAMPLE 1
A. N-{2-[(4-{2-Chlorophenyl}-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyrid-2-yl)methoxy]ethyl}-N'-cyano-S-methyl-isothiourea ##STR23##
2-[2-Aminoethoxymethyl]-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (4.3 g) and dimethyl N-cyanoimidodithiocarbonate (2 g) in isopropanol (15 ml) were allowed to stand at room temperature for 4 hours. Ether (30 ml) was then added and the mixture was stood at room temperature overnight. The crystalline precipitate was filtered, washed with ether and dried, yield of the title compound 5.0 g, m.p. 177.degree.-179.degree..
Analysis %: Found: C, 54.35; H, 5.4; N, 11.2. Calculated for C.sub.23 H.sub.27 ClN.sub.4 O.sub.5 S: C, 54.5; H, 5.4; N, 11.05.
B. 2-[2-(3-Amino-1H-1,2,4-triazol-5-ylamino)ethoxymethyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR24##
N-{2-[(4{-2-Chlorophenyl}-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyrid-2-yl)methoxy]ethyl}-N'-cyano-S-methyl-isothiourea (0.4 g) and hydrazine hydrate (0.15 ml) were dissolved in ethanol (20 ml) and heated under reflux for 3 hours. The solvent was then evaporated and toluene (10 ml) was added to the residue, and again the solution was evaporated to dryness. The residue was chromatographed on Merck "Kieselgel 60H" (Trade Mark), eluting with 2% methanol in methylene chloride, to give a beige solid. The solid was recrystallized from ethyl acetate plus a trace of ether to give the title compound, yield 0.1 g, m.p. 137.degree.-138.degree..
Analysis %: Found: C, 53.45; H, 5.5; N, 17.2. Calculated for C.sub.22 H.sub.27 ClN.sub.6 O.sub.5 : C, 53.8; H, 5.55; N, 17.1.
Part (A) was repeated using (MeO).sub.2 C.dbd.N.CN in place of (MeS).sub.2 C.dbd.N.CN and using the same reaction conditions. The resulting intermediate had --OMe in place of --SMe, and this intermediate was converted by the method of part (B), i.e. using hydrazine hydrate, to the title compound of part (B).
EXAMPLE 2
2-[2-(3-Amino-1H-1,2,4-triazol-5-ylamino)ethoxymethyl]-4-(2-chloro-3-trifluoromethylphenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR25##
2-(2-Aminoethoxymethyl)-4-(2-chloro-3-trifluoromethylphenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (0.5 g) and dimethyl N-cyanoimidodithiocarbonate (0.16 g) in isopropanol (5 ml) were stirred together at room temperature for 4 hours. Ether (10 ml) was then added and the mixture was stirred for a further 2 hours. The precipitated isothiourea was filtered, washed with dry ether, dried and used directly without further purification. The solid was dissolved in ethanol (10 ml) and heated to reflux while hydrazine hydrate (0.2 ml) was added in three portions. After 3 hours at reflux, the solution was evaporated to dryness and the residue was crystallised from ethyl acetate to give the title compound, m.p. 144.degree.-145.degree..
Analysis %: Found: C, 49.4; H, 4.7; N, 15.0. Calculated for C.sub.23 H.sub.26 ClF.sub.3 N.sub.6 O.sub.5 : C, 49.6; H, 4.7; N, 15.0.
EXAMPLE 3
A. The following compound, m.p. 215.degree.-217.degree., was prepared similarly to Example 1A, but starting from the corresponding 4-(2,3-dichlorophenyl)-1,4-dihydropyridyl derivative: ##STR26##
Analysis %: Found: C, 50.7; H, 5.05; N, 10.1. Calculated for C.sub.23 H.sub.26 Cl.sub.2 N.sub.4 O.sub.5 S: C, 51.02; H, 4.85; N, 10.35.
B. This compound was then reacted with hydrazine hydrate according to the procedure of Example 1B to produce the following product, m.p. 195.degree.-6.degree.: ##STR27##
Analysis %: Found: C, 50.2; H, 5.35; N, 15.6. Calculated for C.sub.22 H.sub.26 Cl.sub.2 N.sub.6 O.sub.5.1/4C.sub.4 H.sub.8 O.sub.2 : C, 50.45; H, 5.15; N, 15.35.
EXAMPLE 4
The following compound, m.p. 110.degree.-111.degree., was prepared similarly to Example 1B, but using methyl hydrazine: ##STR28##
Analysis %: Found: C, 54.1; H, 5.8; N, 16.3 Calculated for C.sub.23 H.sub.29 ClN.sub.6 O.sub.5.1/2H.sub.2 O: C, 53.7; H, 5.9; 16.35.
EXAMPLE 5
The following compound m.p. 118.degree.-120.5.degree. was prepared similarly to Example 3B, but using methyl hydrazine: ##STR29##
Analysis %: Found: C, 50.6; H, 5.3; N, 15.0. Calculated for C.sub.23 H.sub.28 Cl.sub.2 N.sub.6 O.sub.5.1/2H.sub.2 O: C, 50.4; H, 5.3; N, 15.3.
EXAMPLE 6
2-[2-(5-Amino-1,2,4-oxadiazol-3-ylamino)ethoxymethyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR30##
The N'-cyano-S-methyl-isothiourea from Example 1A (0.4 g) and hydroxylamine (0.2 g) in methanol (20 ml) were heated under reflux for 3 hours. The solvent was then evaporated, and the residue was chromatographed on "Kieselgel 60H" (Trade Mark), eluting with chloroform to give a solid which was recrystallised from 1:1 toluene/ether to give the title compound, yield 0.29 g, m.p. 135.degree..
Analysis %: Found: C, 53.8; H, 5.4; N, 14.25. Calculated for C.sub.22 H.sub.26 ClN.sub.5 O.sub.6 : C, 53.7; H, 5.3; N, 14.25.
EXAMPLE 7
The following compound, m.p. 114.degree., was prepared similarly to the procedure of Example 6 but using the corresponding 2-chloro-3-trifluoromethyl isothiourea intermediate as prepared in Example 2: ##STR31##
Analysis %: Found: C, 49.6; H, 4.7; N, 12.4. Calculated for C.sub.23 H.sub.25 ClF.sub.3 N.sub.5 O.sub.6 : C, 49.3; H, 4.5; N, 12.5.
EXAMPLE 8
4-(2-Chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(3,4-dihydro-4-oxo-pyrimidin-2-ylamino)ethoxymethyl]-1,4-dihydropyridine ##STR32##
2-[2-Aminoethoxymethyl]-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (0.75 g) and 2-methylthio-3H-pyrimid-4-one (0.5 g) were dissolved in ethanol (5 ml) and heated under reflux for 20 hours. The solvent was evaporated and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with 2N hydrochloric acid to remove any unreacted amine, and then with dilute sodium hydroxide solution. It was then washed with water, dried, filtered and evaporated to give a yellow gum. Chromatography on silica "Kieselgel 60H" (Trade Mark) eluting with ethyl acetate gave the title compound, which was recrystallised from ethyl acetate, yield 171 mg, m.p. 148.degree.-150.degree..
Analysis %: Found: C, 57.3; H, 5.55; N, 11.4. Calculated for C.sub.24 H.sub.27 ClN.sub.4 O.sub.6 : C, 57.3; H, 5.4; N, 11.15.
EXAMPLES 9-36
The following compounds were prepared similarly to the previous Example, i.e., by the following reaction: ##STR33## and were characterised in the form indicated:
__________________________________________________________________________ ##STR34##Ex-am- Analysis %ple Reaction Reaction Form m.p. (Theoretical in brackets)No. R.sup.3 Q Solvent Base Time Isolated (.degree.C.) C H N__________________________________________________________________________ 9 ##STR35## MeS EtOH Et.sub.3 N 4 hrs. Free base 155- 157 55.8 (56.25 5.55 5.55 11.3 11.4)10 ##STR36## Cl CH.sub. 3 CN Na.sub.2 CO.sub.3 6 hrs. Free base 137 59.05 (59.2 5.7 5.6 11.3 11.5)11 ##STR37## Cl MeOH Et.sub.3 N 12 hrs. Free base 186- 189 53.25 (53.3 5.5 5.45 18.6 18.9)12 ##STR38## Cl -n-BuOH Et.sub.3 N 60 hrs. Free base 225 56.5 (57.35 5.4 11.05 11.15)13 ##STR39## Cl -n-BuOH Et.sub.3 N 60 hrs. Free base 172- 174 57.2 (57.4 5.8 5.6 13.8 13.95)14 ##STR40## Cl -n-BuOH Et.sub.3 N 18 hrs. Free base 120- 122 56.9 (57.35 5.3 5.4 10.9 11.15)15 ##STR41## Cl -n-BuOH Et.sub.3 N 18 hrs. Free base, H.sub.2 O 122 55.2 (55.25 5.85 5.9 9.8 9.9)16 ##STR42## Cl CH.sub.3 CN Na.sub.2 CO.sub.3 5 hrs. Free base 153- 155 56.9 (57.0 5.15 5.2 15.9 15.95)17 ##STR43## Cl -n-BuOH Et.sub.3 N 20 hrs. Free base 205- 207 57.35 (58.8 5.3 5.4 8.9 9.15)18 ##STR44## Cl MeOH Et.sub.3 N 2 hrs. Free base 160 55.35 (55.3 5.2 5.0 10.9 10.75)19 ##STR45## Cl D.M.F. Na.sub.2 CO.sub.3 5 hrs. Free base 176- 177 59.75 (59.8 5.4 5.2 7.55 7.75)20 ##STR46## OEt EtOH -- 31/2 hrs. Hydro- chloride 166- 167 56.2 (56.25 6.15 6.1 8.35 8.2)21 ##STR47## SMe EtOH Et.sub.3 N 6 hrs. Acetate 164 55.05 (55.9 6.15 6.2 10.45 10.45)22 ##STR48## Cl -n-BuOH 4- dimethyl- amino- pyridine 18 hrs. Maleate 2.H.sub.2 O 156- 158 53.9 (53.85 5.1 5.0 8.4 8.3)23 ##STR49## SMe EtOH Et.sub.3 N 1 hr. Free base 226- 228 57.5 (57.8 6.0 6.0 10.8 10.8)24 ##STR50## NHNO.sub.2 -n-BuOH -- 18 hrs. Hemi- fumarate 197- 199(d) 56.3 (56.4 5.4 5.4 9.8 9.7)25 ##STR51## Cl -n-BuOH 4-dimethyl- amino- pyridine 18 hrs. Maleate 163.5- 164 56.0 (56.1 5.1 4.7 8.6 8.7)26 ##STR52## Cl -n-BuOH 4-dimethyl- amino- pyridine 24 hrs. Free base 125 50.1 (50.1 5.1 5.2 9.1 9.3)27 ##STR53## Cl -n-BuOH Et.sub.3 N 60 hrs. Free base Hemi- etherate 101- 104 57.7 (57.9 6.2 6.2 12.9 13.0)28 ##STR54## Cl -n-BuOH 4-dimethyl- amino- pyridine 20 hrs. Free base 133- 134 58.4 (58.7 5.2 5.1 13.3 13.7)29 ##STR55## Cl -n-BuOH 4-dimethyl- amino- pyridine 4 hrs. Free base 211 56.5 (56.7 5.3 5.3 13.0 13.2)30 ##STR56## Cl n-BuOH 4-dimethyl- amino- pyridine 18 hrs. 1/2.Ethyl acetate 124- 126 57.4 (57.8 5.8 5.6 10.0 10.0)31 ##STR57## Cl CH.sub.2 Cl.sub.2 Et.sub.3 N 26 hours Free base 115 55.1 (55.3 5.1 5.0 10.6 10.75)32 ##STR58## Cl EtOH Et.sub.3 N 18 hours Free base 110 55.4 (55.3 5.35 5.0 10.4 10.75)33 ##STR59## Cl EtOH Et.sub.3 N 18 hours Free base 142- 144 55.3 (55.3 4.9 5.0 10.6 10.75)34 ##STR60## Cl BuOH 4-Dimethyl- amino pyridine 18 hours Free base 172- 173 58.4 (58.9 5.8 5.6 11.5 11.4)35 ##STR61## Cl BuOH Et.sub.3 N 48 hours Free base 165- 168 53.5 (53.1 5.25 5.2 9.8 9.9)36 ##STR62## Cl EtOH Et.sub.3 N 60 hours Hemi- hydrate 165- 167 53.9 (53.8 5.5 5.6 10.75 10.45)__________________________________________________________________________
EXAMPLES 37-57
The following compounds were prepared similarly to Example 8, i.e. by the following reaction: ##STR63## and were characterised in the form indicated:
__________________________________________________________________________ Analysis %Ex- (Theoreticalample Reaction Reaction Form m.p. in brackets)No R.sup.3 Q Solvent Base Time Isolated (.degree.C.) C H N__________________________________________________________________________37 ##STR64## SMe EtOH Et.sub.3 N 3 hrs. Hemihydrate 218 (d) 51.7 (51.7 5.0 5.1 10.3 10.5)38 ##STR65## SMe EtOH Et.sub.3 N 22 hrs. Free base 225- 227 53.2 (53.4 5.4 5.6 10.0 10.0)39 ##STR66## SMe EtOH Et.sub.3 N 24 hrs. Hemihydrate 142- 145 52.5 (52.7 4.7 5.0 10.4 10.3)40 ##STR67## Cl -n-BuOH Et.sub.3 N 36 hrs. Free base 179 53.5 (53.7 5.2 5.1 13.0 13.1)41 ##STR68## Cl -n-BuOH 4-dimethyl- amino- pyridine 30 hrs. Free base hemi-hydrate 132- 134 52.9 (52.75 4.8 5.0 10.5 10.3)42 ##STR69## NHNO.sub.2 n-BuOH -- 18 hrs. Fumarate 144- 146 52.4 (52.2 4.9 4.8 8.6 8.4)43 ##STR70## NHNO.sub.2 BuOH -- 18 hours Free base 201 56.3 (56.0 4.7 4.8 7.7 8.1)44 ##STR71## NHNO.sub.2 BuOH -- 18 hours Free base 205- 206 56.65 (56.7 4.9 4.8 11.0 11.4)45 ##STR72## Cl BuOH Et.sub.3 N 18 hours. Free base 177.5- 178.5 51.7 (52.0 5.1 5.1 8.5 8.4)46 ##STR73## Cl BuOH 4-Dimethyl amino pyridine 32 hours Sesqui-hydrate 182- 183.5 51.7 (51.9 5.3 5.7 7.9 8.1)47 ##STR74## Cl EtOH Et.sub.3 N 66 hours Free base 101- 104 51.55 (51.7 5.3 5.1 9.0 9.0)48 ##STR75## Cl BuOH 4-Dimethyl amino pyridine 18 hours Free base 190 55.6 (55.7 5.2 5.15 10.6 10.8)49 ##STR76## Cl EtOH Et.sub.3 N 18 hours Free base 101- 103 55.2 (55.5 4.6 5.0 9.00 9.25)50 ##STR77## Cl EtOH Et.sub.3 N 17 hours Free base 148- 150 53.5 (53.6 5.0 4.9 10.4 10.4)51 ##STR78## Cl EtOH Et.sub.3 N 18 hours Free base 111- 112 51.6 (51.9 4.3 4.5 10.2 10.1)52 ##STR79## Cl EtOH Et.sub.3 N 18 hours Free base 113- 115 51.8 (51.9 4.6 4.5 10.0 10.1)53 ##STR80## Cl EtOH Et.sub.3 N 4 hours Free base 110 51.7 (51.9 4.5 4.5 9.9 10.1)54 ##STR81## Cl BuOH Et.sub.3 N 48 hours Free base 162- 164 56.8 (57.0 4.8 5.3 9.2 9.2)55 ##STR82## Cl BuOH Et.sub.3 N 10 hours Free base 146- 148 58.4 (58.7 5.0 4.9 9.3 9.1)56 ##STR83## Cl BuOH Et.sub.3 N 7 hours Free base 158- 160 55.5 (55.3 5.0 5.0 10.9 10.75)57 ##STR84## Cl BuOH Et.sub.3 N 17 hours Free base 137- 139 55.8 (56.0 5.7 5.6 9.8 9.7)__________________________________________________________________________
EXAMPLES 58-63
The following compounds were prepared similarly to Example 8, i.e. by the following reaction: ##STR85## and were characterised in the form indicated:
__________________________________________________________________________ Analysis %Example Reaction Reaction Form m.p. (Theoretical in brackets)No. R.sup.3 Q Solvent Base Time Isolated (.degree.C.) C H N__________________________________________________________________________58 ##STR86## SMe EtOH Et.sub.3 N 4 hours Hemihydrate 206- 208 50.4 (50.75 4.7 4.8 9.7 9.9)59 ##STR87## SMe EtOH -- 24 hours Free Base 139- 140 52.6 (52.6 4.6 4.6 9.85 9.8)60 ##STR88## Cl n-BuOH 4-dimethyl- amino- pyridine 24 hrs. Free Base 135- 136 52.3 (52.6 4.6 4.6 9.7 9.8)61 ##STR89## NH.NO.sub.2 n-BuOH -- 18 hours Free Base 147- 149 53.5 (53.4 5.2 4.8 9.4 9.6)62 ##STR90## SMe n-BuOH -- 72 hours Free Base 128- 130 52.2 (52.6 4.7 4.6 9.9 9.8)63 ##STR91## Cl DMF -- 24 hours HCl.1/2H.sub.2 O 175 50.4 (50.5 4.5 4.7 8.2 8.7)__________________________________________________________________________
EXAMPLE 64
3-{2-[(4-{2,3-Dichlorophenyl}-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyrid-2-yl)methoxy]ethylamino}-4-methoxy-1,2,5-thiadiazole-1-oxid ##STR92##
2-[2-Aminoethoxymethyl]-3-ethoxycarbonyl-4-(2,3-dichlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (0.5 g) and 3,4-dimethoxy-1,2,5-thiadiazole-1-oxide (0.2 g) were dissolved in methanol (15 ml) and heated at reflux for 14 hours. The solvent was evaporated and the residue chromatographed on silica "Kieselgel 60H" (Trade Mark), eluting with ethyl acetate. The product-containing fractions were combined and evaporated to give an oil which was triturated in ethyl acetate to give the title compound as a solid, yield 0.14 g, m.p. 183.degree.-185.degree..
Analysis %: Found: C, 48.1; H, 4.6; N, 9.4. Calculated for C.sub.23 H.sub.26 Cl.sub.2 N.sub.4 O.sub.7 S: C, 48.15; H, 4.55; N, 9.75.
EXAMPLE 65
The following compound, m.p. 158.degree.-160.degree., was prepared similarly to the previous Example, starting from the corresponding 4-(2-chlorophenyl)-1,4-dihydropyridine and 3,4-dimethoxy-1,2,5-thiadiazole-1-oxide. The reaction time was 18 hours, and the solvent methanol: ##STR93##
Analysis %: Found: C, 52.0; H, 5.4; N, 10.1. Calculated for C.sub.23 H.sub.27 ClN.sub.4 O.sub.7 S: C, 51.25; H, 5.0; N, 10.4.
EXAMPLE 66
The following compound, m.p. 139.degree.-141.degree., was prepared similarly to Example 64, starting from the corresponding 4-(2-chloro-3-trifluoromethylphenyl)-1,4-dihydropyridine and 3,4-dimethoxy-1,2,5-thiadiazole-1-oxide. The reaction time was 18 hours, and the solvent methanol: ##STR94##
Analysis %: Found: C, 47.3; H, 4.4; N, 9.4. Calculated for C.sub.24 H.sub.26 ClF.sub.3 N.sub.4 O.sub.7 S: C, 47.5; H, 4.3; N, 9.2.
EXAMPLE 67
3-{2-[(4-{2,3-Dichlorophenyl}-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyrid-2-yl)methoxy]ethylamino}-4-amino-1,2,5-thiadiazole-1-oxide hemihydrate ##STR95##
3-{-2-[(4-{2,3-Dichlorophenyl}-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyrid-2-yl)methoxy]ethylamino}-4-methoxy-1,2,5-thiadiazole-1-oxide (0.3 g) was dissolved in ethanolic ammonia (10 ml) and stirred at room temperature for 1 hour. The solvent was evaporated and the residue chromatographed on silica "Kieselgel 60H" (Trade Mark), eluting with ethyl acetate. The product containing fractions were combined and evaporated to give an oil which was triturated with ethyl acetate to give the title compound as a solid, yield 0.15 g, m.p. 135.degree..
Analysis %: Found: C, 46.6; H, 4.6; N, 12.1. Calculated for C.sub.22 H.sub.25 Cl.sub.2 N.sub.5 O.sub.6 S.1/2H.sub.2 O: C, 46.6; H, 4.6; N, 12.3.
EXAMPLE 68
The following compound, m.p. 130.degree., was prepared similarly to the previous Example, starting from the corresponding 2-chlorophenyl compound and ammonia/EtOH. The reaction time was 1.5 hours: ##STR96##
Analysis %: Found: C, 50.4; H, 5.3; N, 13.3. Calculated for C.sub.22 H.sub.26 ClN.sub.5 O.sub.6 S: C, 50.4; H, 5.0; N, 13.4.
EXAMPLE 69
The following compound, m.p. 142.degree.-145.degree., was prepared similarly to Example 67, starting from the corresponding 2-chloro-3-trifluoromethylphenyl compound and ammonia/ethanol. The reaction time was one hour: ##STR97##
Analysis %: Found: C, 45.6; H, 4.5; N, 11.6. Calculated for C.sub.23 H.sub.25 ClF.sub.3 N.sub.5 O.sub.6 S:1/2H.sub.2 O: C, 46.0; H, 4.4; N, 11.65.
EXAMPLE 70
4-(2-Chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(2-thiazolin-2-ylamino)ethoxymethyl]-1,4-dihydropyridine ##STR98##
2-[2-Aminoethoxymethyl]-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (0.5 g), triethylamine (0.3 ml) and 2-chloroethylisothiocyanate (0.16 ml) were dissolved in methylene chloride (5 ml) and the mixture was stirred at room temperature for 2 hours. The mixture was then washed with water (5 ml), dried, filtered and evaporated to give a gum. Chromatography of the gum on silica "Kieselgel 60H" (Trade Mark) eluting initially with toluene then with chloroform with a trace of methanol gave the title compound, which was recrystallised from ether, yield 0.102 g, m.p. 145.degree.-147.degree..
Analysis %: Found: C, 55.6; H, 5.75; N, 8.3. Calculated for C.sub.23 H.sub.28 ClN.sub.3 O.sub.5 S: C, 55.6; H, 5.75; N, 8.3.
EXAMPLE 71
4-(2-Chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(thiazol-2-ylamino)ethoxymethyl]-1,4-dihydropyridine ##STR99##
(a) Thiophosgene (0.9 ml) was added to a stirred mixture of 2-(2-aminoethoxymethyl)-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (4.08 g) and powdered calcium carbonate (3 g) in methylene chloride (25 ml) and water (35 ml). The mixture was stirred overnight at room temperature, filtered, and partitioned between 2N hydrochloric acid and methylene chloride. The organic layer was washed with water, dried (Na.sub.2 CO.sub.3), filtered and evaporated to give the intermediate isothiocyanate as a solid.
This solid was used directly in the next stage of the reaction without further purification.
(b) The isothiocyanate from part (a) (4 g) was heated in ethanolic ammonia solution for 21/2 hours. The resulting precipitate was filtered and recrystallised from ethanol/methylene chloride (5:1) to give the intermediate thiourea, yield 3.8 g, m.p. 203.5.degree.-204.5.degree..
Analysis %: Found: C, 53.3; H, 5.5; N, 8.6. Calculated for C.sub.21 H.sub.26 N.sub.3 ClO.sub.5 S: C, 53.8; H, 5.6; N, 8.9.
(c) The thiourea from part (b) (0.2 g) and chloroacetaldehyde (0.1 g) were dissolved in a 1:1 mixture of chloroform/methanol and the mixture was stirred at room temperature overnight. Removal of the solvent by evaporation left an oil to which toluene (10 ml) was added. After removal of the toluene by evaporation the residue was chromatographed on silica ["Kieselgel 60H" (Trade Mark)]. Elution with toluene, ethyl acetate and finally ethyl acetate/1% methanol afforded a white solid which was recrystallised from ether to give the title compound, yield 0.075 g, m.p. 134.degree..
Analysis %: Found: C, 56.0; H, 5.4; N, 8.4. Calculated for C.sub.23 H.sub.26 ClN.sub.3 O.sub.5 S: C, 56.15; H, 5.3; N, 8.5.
EXAMPLES 72-74
The following compounds were prepared similarly to the method described in part (c) of the previous Example, starting from the same intermediate thiourea and, respectively, ClCH.sub.2 COCH.sub.3, BrCH.sub.2 COCOOEt and BrCH.sub.2 COOEt.
__________________________________________________________________________ ##STR100## Analysis %Example Reaction Reaction (Theoretical in brackets)No. R.sup.3 Solvent Time m.p. (.degree.C.) C H N__________________________________________________________________________72 ##STR101## 5:1:0.5 CH.sub.2 Cl.sub.2 : MeOH: Et.sub.3 N 3 hrs., reflux temp. 147.degree. 56.7 (56.95 5.75 5.6 8.05 8.3)73 ##STR102## 10:1:0.5 CHCl.sub.3 : MeOH: Et.sub.3 N 18 hrs., room temp. 129-131.degree. 55.3 (55.35 5.75 5.35 7.15 7.45)74 ##STR103## 100:1 CH.sub.2 Cl.sub.2 : Et.sub.3 N 12 hrs., room temp. 160-162.degree. 54.1 (54.4 5.2 5.2 8.1 8.3)__________________________________________________________________________
EXAMPLE 75
The following compound, m.p. 190.degree.-192.degree. was prepared similarly to Example 74 but starting from the corresponding 2-chloro-3-trifluoromethyl 1,4-dihydropyridine and without isolation of the intermediates. The reaction time was 20 hours: ##STR104##
Analysis %: Found: C, 50.1; H, 4.3; N, 7.1. Calculated for C.sub.24 H.sub.25 ClF.sub.3 N.sub.3 O.sub.6 S: C, 50.0; H, 4.4; N, 7.3.
EXAMPLE 76
Preparation of 4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(4-oxo-2-thiazolin-2-ylamino)ethoxymethyl]-1,4-dihydropyridine ##STR105##
The title compound, m.p. 204.degree.-205.degree., was prepared by a method similar to that in Example 74 but starting with the corresponding 4-(2,3-dichlorophenyl)1,4-dihydropyridine. The reaction conditions were the same:
Analysis %: Found: C, 51.2; H, 4.7; N, 7.7. Calculated for C.sub.23 H.sub.25 Cl.sub.2 N.sub.5 O.sub.6 S: C, 50.9; H, 4.65; N, 7.75.
EXAMPLE 77
4-(2-Chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(4-[N-methylcarbamoyl]-thiazol-2-ylamino)ethoxymethyl]-1,4-dihydropyridine ##STR106##
The ester product of Example 73 (0.1 g) was dissolved in a 33% solution of methylamine in ethanol (10 ml) and the mixture was stood at room temperature overnight and then warmed briefly on a steam bath. The solvent was removed by evaporation and the residue chromatographed on silica "Kieselgel 60H" (Trade Mark). Elution with toluene and then 1:2 toluene/ethyl acetate afforded a solid which was recrystallised from ether to give the title compound, yield 52 mg, m.p. 120.degree..
Analysis %: Found: C, 54.35; H, 5.3; N, 10.2. Calculated for C.sub.25 H.sub.29 ClN.sub.4 O.sub.6 S: C, 54.7; H, 5.3; N, 10.2.
EXAMPLE 78
2-[2-(4,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-ylamino)ethoxymethyl]-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine monohydrate ##STR107##
N-{2-[4-{2,3-Dichlorophenyl}-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyrid-2-yl)methoxy]ethyl}-N'-cyano-S-methyl-isothiourea (400 mg) was added to a solution of hydroxylamine hydrochloride (57 mg) and sodium methoxide (44 mg) in methanol (10 ml) and heated under reflux for 1 hour. The solution was evaporated to dryness and the residue taken up in ethyl acetate and washed with 2M hydrochloric acid and aqueous sodium carbonate. The organic layer was dried over magnesium sulphate, filtered and evaporated. The residue was chromatographed on "Merck" (Trade Mark) J60 silica eluting with ethyl acetate. The product containing fractions were combined and evaporated to dryness, trituration with ether giving the title compound (70 mg), m.p. 132.degree.-134.degree..
Analysis %: Found: C, 48.45; H, 4.8; N, 10.3. Calculated for C.sub.22 H.sub.24 Cl.sub.2 N.sub.4 O.sub.7.H.sub.2 O: C, 48.3; H, 4.9; N, 10.5.
EXAMPLE 79
2-[2-(2-Methyl-3-{3-methylureido}-2H-1,2,4-triazol-5-ylamino)ethoxymethyl]-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine hydrate ##STR108##
A solution of (1) (0.2 g; product of Example 4) and methyl isocyanate (0.6 ml) in methylene chloride (50 ml) was stirred at room temperature for 18 hours. The solvent was evaporated to dryness and the residue was chromatographed on Merck (Trade Mark) J60 silica eluting with 5% methanol in methylene chloride. The product-containing fractions were combined and evaporated to dryness, trituration with ethyl acetate giving the title compound, yield 0.04 g; m.p. 110.degree.-112.degree..
Analysis %: Found: C, 51.8; H, 5.9; N, 16.9. Calculated for C.sub.25 H.sub.32 ClN.sub.7 O.sub.6.H.sub.2 O: C, 51.8; H, 5.9; N, 17.1.
EXAMPLE 80
4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-[2-(6-morpholinopyrimidin-4-ylamino)ethoxymethyl]-1,4-dihydropyridine ##STR109##
4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(6-chloropyridin-4-ylamino)ethoxymethyl]-1,4-dihydropyridine (0.5 g) (Product of Example 53) and morpholine (5 ml) were heated together on a steam bath for 18 hours. The excess morpholine was then evaporated and the residue was taken up in ethyl acetate, filtered and chromatographed on silica "Kieselgel 60H" (Trade Mark) eluting with ethyl acetate. The product-containing fractions were combined and evaporated to dryness, trituration with ether giving the title compound (165 mg), m.p. 163.degree..
Analysis %: Found: C, 55.1; H, 5.5; N, 11.2. Calculated for C.sub.28 H.sub.33 Cl.sub.2 N.sub.5 O.sub.6 : C, 55.45; H, 5.5; N, 11.55.
EXAMPLES 81-84
The following compounds were prepared similarly to the previous Example, i.e. by the following reaction, ##STR110## and were characterised in the form indicated:
__________________________________________________________________________ No.Example ##STR111## SolventReaction TimeReaction IsolatedForm (.degree.C.)m.p. CHN(Theoretical in brackets)Analysis__________________________________________________________________________ %81 ##STR112## -- 18 hours Free base 168-170 56.5 (56.2 5.9 5.9 13.4 13.6)82 ##STR113## -- 18 hours Free base 140-142 57.9 (57.6 5.7 5.8 11.2 11.6)83 ##STR114## EtOH 18 hours Free base 158 54.2 (54.55 5.2 5.3 12.8 12.7)84 ##STR115## EtOH 30 hours Free base 88-90 54.5 (54.55 5.55 5.3 12.6 12.7)__________________________________________________________________________
EXAMPLES 85-87
The following compounds were prepared similarly to Example 80, i.e. by the following reaction ##STR116## and were characterised in the form indicated:
__________________________________________________________________________ No.Example ##STR117## SolventReaction TimeReaction IsolatedForm (.degree.C.)m.p. CHN(Theoretical in brackets)Analysis__________________________________________________________________________ %85 ##STR118## -- 18 hours Hydrate 147 59.4 (59.2 6.4 6.5 11.8 11.9)86 ##STR119## -- 20 hours Hemi-fumarate Hemi-hydrate 171 56.4 (56.3 5.8 5.75 10.95 11.3)87 ##STR120## -- 18 hours Free base 133-134 58.45 (58.8 6.0 6.0 12.4 12.2)__________________________________________________________________________
EXAMPLE 88
4-(2-Chloro-3-trifluoromethylphenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-[2-(6-morpholino-pyrimidin-4-ylamino)ethoxymethyl]-1,4-dihydropyridin ##STR121##
4-(2-Chloro-3-trifluoromethylphenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(6-chloropyrimidin-4-ylamino)ethoxymethyl]-1,4-dihydropyridine was prepared similarly to the procedure of Example 53 from appropriate starting materials and was reacted unpurified with morpholine by a procedure similar to that of Example 80 to give the title compound, m.p. 117.degree.-118.degree..
Analysis %: Found: C, 54.0; H, 5.6; N, 10.7. Calculated for C.sub.29 H.sub.33 ClF.sub.3 N.sub.5 O.sub.6 : C, 54.4; H, 5.2; N, 10.9%.
EXAMPLE 89
4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(pyrazin-2-ylamino)ethoxymethyl]-1,4-dihydropyridine ##STR122##
The N-oxide of 4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-(pyrazin-2-ylamino)ethoxymethyl]-1,4-dihydropyridine (0.35 g) (product of Example 50) was heated on a steam bath in 50% aqueous ethanol (15 ml), to which was added sodium dithionite (2 g) portionwise over 1.5 hours. The reaction mixture was then heated for a further 1.5 hours before the solvent was evaporated and the residue partitioned between ethyl acetate and water. The organic layer was separated, dried, filtered and evaporated to give an oil. Chromatography on silica "Kiesgel 60H" (Trade Mark) eluting with ether gave an oil which afforded the title compound when triturated with diisopropyl ether, yield 134 mg., m.p. 113.degree..
Analysis %: Found: C, 55.2; H, 4.9; N, 10.6. Calculated for C.sub.24 H.sub.26 Cl.sub.2 N.sub.4 O.sub.5 : C, 55.3; H, 5.0; N, 10.75.
EXAMPLE 90
(A.) Preparation of 4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-2-[2-(3-ethoxycarbonylthioureido)ethoxymethyl]-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR123##
To a suspension of 2-(2-aminoethoxymethyl)-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (4.43 g) in dry chloroform (50 ml) was added, dropwise, a solution of ethoxycarbonylisothiocyanate (1.31 g) in dry chloroform (25 ml). The reaction was stirred for 18 hours at room temperature before evaporating the solvent and triturating the residue with ether to afford a solid which was recrystallised from diisopropyl ether to give the title compound, yield 2.6 g, m.p. 144.degree..
Analysis %: Found: C, 50.6; H, 5.2; N, 7.0. Calculated for C.sub.24 H.sub.29 Cl.sub.2 N.sub.3 O.sub.7 S: C, 50.2; H, 5.1; N, 7.3.
(B.) Preparation of 4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-2-[2-(5-hydroxy-1H-1,2,4-triazol-3-ylamino)ethoxymethyl]-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine hydrate ##STR124##
To a suspension of 4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-2-[2-(3-ethoxycarbonylthioureido)ethoxymethyl]-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (0.25 g) in dry tetrahydrofuran (THF) (5 ml) was added sodium hydride (0.02 g). After stirring for 1 hour at room temperature a solution of methyl iodide (0.07 g) in dry THF (5 ml) was added dropwise and stirring was continued overnight. After evaporation of the solvent, the residue was taken up in methylene chloride and washed (aqueous NaCl), dried (MgSO.sub.4), filtered and evaporated to give a yellow oil (150 mgs).
The oil was dissolved in isopropanol (5 ml) containing hydrazine hydrate (0.06 g) and heated under reflux for 2 days. The solution was then evaporated and the residue taken up in methylene chloride and washed (aqueous NaHCO.sub.3), dried (MgSO.sub.4), filtered and evaporated. The residue was then chromatographed on silica "Kieselgel 60 H" (Trade Mark), eluting with ethyl acetate/methanol (1% increments up to 20% methanol). Product-containing fractions were combined, evaporated and recrystallised from ethyl acetate to afford the title compound, yield 0.048 g, m.pt. 158.degree..
Analysis %: Found: C, 48.5; H, 4.8; N, 13.0. Calculated for C.sub.22 H.sub.25 Cl.sub.2 N.sub.5 O.sub.6.H.sub.2 O: C, 48.5; H, 5.0; N, 12.9.
EXAMPLE 91
(A) Preparation of 4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-2-[2-(5-hydroxy-4-methylpyrimidin-2-ylamino)ethoxymethyl]-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR125##
A mixture of 2-(2-aminoethoxymethyl)-3-ethoxycarbonyl-4-2,3-dichlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (3.6 g) and 5-acetyl-2-amino-oxazole (0.5 g) in methanol (2 ml) and water (3 ml) was heated on a steam bath for 24 hours. The mixture was then evaporated to dryness and the residue was chromatographed on silica "Kieselgel 60H" (Trade Mark) eluging with ethyl acetate. The product-containing fractions were combined, evaporated and the residue triturated with ether to give the title compound (0.1 g), m.p. 165.degree..
Analysis %: Found: C, 54.3; H, 5.2; N, 10.2. Calculated for C.sub.25 H.sub.28 Cl.sub.2 N.sub.4 O.sub.6 : C, 54.45; H, 5.1; N, 10.2%.
(B) Preparation of 2-[2-(4-acetylimidazol-2-ylamino)ethoxymethyl]-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR126##
From the same reaction described in Part (A) a second, more polar product was subsequently eluted from the chromatography column using ethyl acetate as the eluent. The fractions containing this second product were combined, evaporated and the residue was redissolved in methylene chloride, washed with dilute hydrochloric acid then with aqueous sodium bicarbonate, dried (MgSO.sub.4), filtered and evaporated. The residue was recrystallised from ethyl acetate to give the title compound (0.14 g), m.p. 177.degree..
Analysis %: Found: C, 54.6; H, 5.5; N, 9.9. Calculated for C.sub.25 H.sub.28 Cl.sub.2 N.sub.4 O.sub.6 : C, 54.45; H, 5.1; N, 10.2%.
EXAMPLES 92-97
The following compounds were prepared similarly to the procedure of Example 8, i.e., by the following reaction:
__________________________________________________________________________ ##STR127## Analysis %Example Reaction Reaction Form m.p. (Theoretical in brackets)No. R.sup.3 Q Solvent Base Time Isolated (.degree.C.) C H N__________________________________________________________________________92 ##STR128## Cl nBuOH 4-dimethyl- amino pyridine 24 hrs. Free base hemi-hydrate 139-141 53.15 (52.75 5.1 5.0 10.6 10.25)93 ##STR129## Cl nBuOH Et.sub.3 N 33 hours Hemi-fumarate 197-199 52.4 (52.4 4.9 4.7 9.3 9.4)94 ##STR130## NHNO.sub.2 EtOH -- 18 hours Free base sesqui-hydrate 222 51.6 (51.9 5.4 5.4 9.7 9.4)95 ##STR131## SMe EtOH -- 18 hours Hydrochloride 203-205 (50.0 (50.2 4.9 4.7 9.9 9.8)96 ##STR132## SMe EtOH Et.sub.3 N 17 hours Hydrochloride hemi-hydrate 195-198 48.5 (48.3 4.8 4.9 9.85 9.8)97 ##STR133## Cl EtOH Et.sub.3 N 50 hours Free base 153 51.8 (51.9 4.6 4.5 9.95 10.1)__________________________________________________________________________
EXAMPLES 98-102
The following compounds were prepared similarly to the procedure of the stated Example from appropriate starting materials:
__________________________________________________________________________ ##STR134## Prepared similarly Analysis %Example to the procedure of m.p. (Theoretical in brackets)No. Example no. R.sup.3 (.degree.C.) Form Isolated C H N__________________________________________________________________________ 98 74 ##STR135## 194-196 Free base 50.7 (50.9 4.8 4.65 7.7 7.75) 99 80 ##STR136## 167-169 Free base 55.5 (55.45 5.6 5.5 11.4 11.55)100 1 ##STR137## 173-175 Free base hemi-hydrate 49.3 (49.4 5.05 5.1 15.5 15.7)101 64 ##STR138## 138-140 Free base 48.1 (48.2 4.9 4.6 9.7 9.8)102 67 ##STR139## 142-144 Free base hemi-hydrate 46.35 (46.6 4.9 4.6 12.3 12.3)__________________________________________________________________________
The following Preparations illustrate the preparation of certain starting materials. All temperatures are in .degree.C.:
PREPARATION 1
Preparation of 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate ##STR140##
A suspension of 2-(2-azidoethoxymethyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine (103 g) in ethanol (2.5 l) was stirred for 16 hours at room temperature under one atmosphere of hydrogen in the presence of 5% palladium on calcium carbonate (40 g). The reaction mixture was filtered and evaporated and the residue treated with a solution of maleic acid (22 g) in ethanol (100 ml). The reaction mixture was stirred at room temperature for 2 hours and then the resulting solid collected, washed with ethanol, and dried to give the title compound (100 g), m.p. 169.degree.-170.5.degree..
Analysis %: Found: C, 54.82; H, 5.62; N, 5.46. C.sub.24 H.sub.29 ClN.sub.2 O.sub.9 requires: C, 54.91; H, 5.57; N, 5.34.
PREPARATION 2
2-[2-Aminoethoxymethyl]-4-[2,3-dichlorophenyl]-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine, m.p. 171.degree.-3.degree., was prepared similarly to the previous preparation from the appropriate azido compound, and was characterised as the hemifumarate hemihydrate.
Analysis %: Found: C, 51.7; H, 5.3; N, 5.5. Calculated for C.sub.20 H.sub.24 Cl.sub.2 N.sub.2 O.sub.5.1/2C.sub.4 H.sub.4 O.sub.4.1/2H.sub.2 O: C, 51.8; H, 5.3; N, 5.5.
The hemifumarate was neutralised to the free base form, m.p. 120.degree.-122.degree..
PREPARATION 3
2-(2-Azidoethoxymethyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine
A solution of 2-azidoethanol (160 g) in tetrahydrofuran (300 ml) was added over 40 minutes to a suspension of sodium hydride (114 g; 80% dispersion in oil) in tetrahydrofuran (500 ml). The mixture was stirred at room temperature for 1 hour and the ice-cooled solution treated with a solution of ethyl 4-chloroacetoacetate (276 g) in tetrahydrofuran (250 ml) dropwise over 2 hours. The mixture was stirred at room temperature for 16 hours, diluted with ethanol (150 ml), and the pH adjusted to 6-7 with 4M hydrochloric acid. Sufficient water was added to dissolve the solid present and the layers were separated. The organic layer was evaporated and the residue diluted with water (600 ml) and evaporated. The residue was partitioned between ethyl acetate and water and the aqueous layer extracted twice with ethyl acetate. The combined ethyl acetate extracts were dried (MgSO.sub.4) and evaporated to give ethyl 4-(2-azidoethoxy)acetoacetate as a brown oil, which was shown by g.l.c. to be 73% pure. A mixture of this crude product and ammonium acetate (92.3 g) in ethanol (600 ml) was heated under reflux for 1 hour, allowed to cool to room temperature, and treated with methyl 2-(2-chlorobenzylidene) acetoacetate (286.6 g). The mixture was heated under reflux for 5.5 hours and then evaporated. The residue was stirred with methanol (1.5 l) for 16 hours and the resulting solid collected, washed twice with methanol, dried, and recrystallised from methanol to give the title compound (78 g), m.p. 145.degree.-146.degree..
Analysis %: Found: C, 55.39; H, 5.37; N, 13.01. Calculated for C.sub.20 H.sub.23 ClN.sub.4 O.sub.5 : C, 55.23; H, 5.33; N, 12.88.
PREPARATION 4
2-(2-Azidoethoxy)methyl-4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyrine was prepared by the method described in Preparation 3 using methyl 2-(2,3-dichlorobenzylidene)acetoacetate instead of methyl 2-(2-chlorobenzylidene)acetoacetate. The product had an m.p. of 141.degree..
Analysis %: Found: C, 50.88; H, 4.78; N, 11.73. Calculated for C.sub.20 H.sub.22 Cl.sub.2 N.sub.4 O.sub.5 : C, 51.18; H, 4.73; N, 11.94.
PREPARATION 5
(i) Preparation of Ethyl-4-(2-phthalimidoethoxy)acetoacetate ##STR141##
To a slurry of sodium hydride (57% dispersion in oil, 66.1 g; 1.57M), in tetrahydrofuran (500 ml) cooled to 0.degree. under nitrogen was added B 2-phthalimidoethanol (150 g; 0.785M) followed by ethyl 4-chloroacetoacetate (129 g; 0.785M) in tetrahydrofuran (250 ml) over 1 hour. The mixture was stirred at room temperature overnight then poured into a mixture of 1M hydrochloric acid (800 ml) and ethyl acetate (750 ml). The organic phase was separated and the solvent was evaporated at reduced pressure. The residue separated into two layers and the upper layer of mineral oil was removed to leave the title compound (243 g) as a crude product which was used without further purification.
(ii) Preparation of 4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2-[2-phthalimidoethoxymethyl]-1,4-dihydropyridine ##STR142##
Methyl 3-aminocrotonate (72.2 g; 0.627M) and 2-chlorobenzaldehyde (88.1 g; 0.627M) were added to a solution of ethyl 4-(2-phthalimidoethoxy)acetoacetate (200 g; 0.627M) in isopropanol (1 liter) and the mixture was heated under reflux for 20 hours. The isopropanol was evaporated under reduced pressure and replaced by acetic acid (1 liter). After granulation at 10.degree. the solid was collected and slurried in methanol (300 ml). The solid was collected by filtration and dried in vacuo at 50.degree. to afford the title compound, yield 84.4 g, m.p. 146.degree.-147.degree..
Analysis %: Found: C, 62.2; H, 5.0; N, 5.2. Calculated for C.sub.28 H.sub.27 ClN.sub.2 O.sub.7 : C, 62.4; H, 5.05; N, 5.2.
PREPARATION 6
The following compound, m.p. 148.degree.-150.degree., was prepared similarly to the previous Preparation but using the corresponding 2,3-dichlorobenzaldehyde. The reaction time was the same: ##STR143##
Analysis %: Found: C, 58.7; H, 4.5; N, 5.0. Calculated for C.sub.28 H.sub.26 Cl.sub.2 N.sub.2 O.sub.7 : C, 58.6; H, 4.6; N, 4.9.
PREPARATION 7
Preparation of 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-1,4-dihydropyridine maleate ##STR144##
The intermediate phthalimido compound from Preparation 5 (400 g) was suspended in ethanol (6 liters) containing hydrazine hydrate (111 g) and heated under reflux for 2 hours. After cooling the reaction mixture was filtered and the filtrate was evaporated to give a yellow oil. The oil was taken up in methylene chloride (6.5 liters), washed (H.sub.2 O), dried (MgSO.sub.4) and evaporated. The residue was taken up in hot methylated spirit (1.2 liters) and diluted with hot methylated spirit (400 ml) containing maleic acid (86 g). After cooling the title compound crystallised out as its maleate salt, yield 303 g, m.p. 169.degree.-171.degree..
Analysis %: Found: C, 54.8; H, 5.55; N, 5.3. Calculated for C.sub.20 H.sub.25 ClN.sub.2 O.sub.5.C.sub.4 H.sub.4 O.sub.4 : C, 54.9; H, 5.6; N, 5.3.
PREPARATION 8
The following compound, m.p. 171.degree.-173.degree. was prepared similarly to the previous preparation but starting from the corresponding 2,3-dichlorophenyl compound: ##STR145##
Analysis %: Found: C, 51.55; H, 5.3; N, 5.4. Calculated for C.sub.20 H.sub.24 Cl.sub.2 N.sub.2 O.sub.5.C.sub.4 H.sub.4 O.sub.4.1/2H.sub.2 O: C, 51.5; H, 5.05; N, 5.0.
PREPARATION 9
The following compound, m.p. 179.degree., was prepared similarly to Preparation 5 but using the corresponding 2-chloro-3-trifluoromethylbenzaldehyde in stage (ii). The reaction time was the same: ##STR146##
Analysis %: Found: C, 57.2; H, 4.45; N, 4.8. Calculated for C.sub.29 H.sub.26 ClF.sub.3 N.sub.2 O.sub.7 : C, 57.4; H, 4.3; N, 4.6.
PREPARATION 10
Preparation of 2-(2-Azidoethoxymethyl)-4-(2-chloro-3-trifluoromethylphenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR147##
The title compound, m.p. 143.degree.-145.degree., was prepared similarly to the method described in Preparation 3 but using the corresponding 2-chloro-3-trifluoromethylbenzaldehyde. The reaction time was the same:
Analysis %: Found: C, 50.2; H, 4.4; N, 11.3. Calculated for C.sub.21 H.sub.22 ClF.sub.3 N.sub.4 O.sub.5 : C, 50.15; H, 4.4; N, 11.1.
PREPARATION 11
Preparation of 2-[2-Aminoethoxymethyl]-4-(2-chloro-3-trifluoromethylphenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR148##
The title compound was prepared by the catalytic hydrogenation of the azido compound of Preparation 10 by the method described in Preparation 1. This compound was confirmed by n.m.r. and i.r. analysis to be identical to the product of Preparation 13.
PREPARATION 12
Preparation of 2-(2-Azidoethoxymethyl)-4-(2,3-dichlorophenyl)-3-methoxycarbonyl-5-ethoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR149##
The title compound, m.p. 126.degree., was prepared similarly to the method described in Preparation 3 but using methyl 4-bromoacetoacetate instead of ethyl 4-chloroacetoacetate yielding methyl 4-(2-azidoethoxy)acetoacetate instead of ethyl 4-(2-azidoethoxy)acetoacetate. The other conditions were the same:
Analysis %: Found: C, 51.3; H, 4.7; N, 12.1. Calculated for C.sub.20 H.sub.22 Cl.sub.2 N.sub.4 O.sub.5 : C, 51.2; H, 4.7; N, 11.9.
PREPARATION 13
Preparation of 2-(2-aminoethoxymethyl)-4-(2-chloro-3-trifluoromethylphenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine ##STR150##
The intermediate phthalimido compound from Preparation 9 (2.8 g) was added to aqueous methylamine (14 ml of 40%) and stirred at room temperature for 17 hours. The resultant solid was filtered, redissolved in chloroform (50 ml), dried (MgSO.sub.4), filtered and evaporated to give a yellow solid. Crystallisation from hexane gave the title compound, yield 1.0 g, m.p. 122.degree..
Analysis %: Found: C, 53.25; H, 4.9; N, 5.75. Calculated for C.sub.21 H.sub.24 ClF.sub.3 N.sub.2 O.sub.5 : C, 52.9; H, 5.1; N, 5.9.
PREPARATION 14
Preparation of 4-(2,3-dichlorophenyl)-5-ethoxycarbonyl-3-methoxycarbonyl-6-methyl-2-[2-phthalimidoethoxymethyl]-1,4-dihydropyridine ##STR151##
The title compound, m.p. 165.degree., was prepared similarly to the method described in Preparation 5(ii) but using 2,3-dichlorobenzaldehyde, methyl 4-(2-phthalimidoethoxy)-acetoacetate and ethyl 3-aminocrotonate. The reaction time was the same:
Analysis %: Found: C, 58.5; H, 4.7; N, 5.0. Calculated for C.sub.28 H.sub.26 Cl.sub.2 N.sub.2 O.sub.7 : C, 58.65; H, 4.6; N, 4.9.
The starting acetoacetate was prepared similarly to Preparation 5(i).
PREPARATION 15
Preparation of 2-(2-aminoethoxymethyl)-4-(2,3-dichlorophenyl)-5-ethoxycarbonyl-6-methyl-3-methoxycarbonyl-1,4-dihydropyridine ##STR152##
The title compound, m.p. 131.degree.-132.degree., was prepared similarly to the method described in Preparation 13 but using the material from Preparation 14.
Analysis %: Found: C, 53.9; H, 5.5; N, 6.4. Calculated for C.sub.20 H.sub.24 Cl.sub.2 N.sub.2 O.sub.5 : C, 54.2; H, 5.5; N, 6.3.
PREPARATION 16
Preparation of 2-chloro-3-trifluoromethylbenzaldehyde
2-Chloro-1-trifluoromethylbenzene (54.15 g) was dissolved in dry tetrahydrofuran (500 ml) and stirred while cooling to -68.degree. under a stream of dry nitrogen. (The whole reaction is carried out under dry nitrogen until the addition of distilled water.) To this was added n-butyl lithium (180 ml of a 1.6M solution in hexane) dropwise keeping the temperature below -60.degree.. After stirring at -68.degree. for a further 2 hours, a solution of dimethylformamide (22 ml) in dry tetrahydrofuran (100 ml) was added dropwise keeping the temperature below -60.degree.. The reaction mixture was allowed to warm to room temperature slowly over 17 hours and distilled water (200 ml) was then added. The organic phase was separated off and the aqueous liquors were extracted with ether (100 ml). The combined ether extracts plus the organic phase were washed with saturated brine, dried (MgSO.sub.4), filtered and evaporated to give 61.5 g of an orange oil, being the crude title compound.
This oil was then added to an aqueous sodium bisulphite solution (65 g in 600 ml distilled water) and heated at 60.degree. for 0.5 hours. The solution was extracted with methylene chloride (3.times.100 ml) and, after acidification of the aqueous phase with concentrated sulphuric acid to pH1, was heated at 100.degree. for a further 0.5 hours. The resultant aqueous solution was extracted with methylene chloride (3.times.200 ml) and the combined organic extracts were dried (MgSO.sub.4), filtered and evaporated to give 42 g of a colourless solid which was crystallised from hexane to give the title compound, m.p. 43.degree.-44.degree..
Analysis %: Found: C, 45.9; H, 2.0. Calculated for C.sub.8 H.sub.4 F.sub.3 ClO: C, 46.1; H, 2.0.
PREPARATION 17
Preparation of 2,3-dichlorobenzaldehyde
A similar route to that described in the previous Preparation, starting from 1,2-dichlorobenzene, proved to be a superior method for preparing the title compound, m.p. 62.degree..
Analysis %: Found: C, 47.62; H, 2.38. Calculated for C.sub.7 H.sub.4 Cl.sub.2 O: C, 48.04; H, 2.30.
ACTIVITY DATA
The molar concentrations of the compounds required to reduce the response by 50% in the test specified on pages 16-17 are given below (1M=1 gm.Mole/liter). The smaller the concentration the more active the compound.
______________________________________Compound IC.sub.50______________________________________Product of Example 1B 2 .times. 10.sup.-8 MProduct of Example 2 2.29 .times. 10.sup.-9 MProduct of Example 3B 6.02 .times. 10.sup.-9 MProduct of Example 4 8.12 .times. 10.sup.-9 MProduct of Example 5 3.02 .times. 10.sup.-9 MProduct of Example 6 1.15 .times. 10.sup.-8 MProduct of Example 7 3.47 .times. 10.sup.-9 MProduct of Example 8 1.05 .times. 10.sup.-8 MProduct of Example 9 1.26 .times. 10.sup.-8 MProduct of Example 10 1.9 .times. 10.sup.-9 MProduct of Example 11 4.26 .times. 10.sup.-7 MProduct of Example 12 2.88 .times. 10.sup.-8 MProduct of Example 13 6.3 .times. 10.sup.-9 MProduct of Example 14 1.0 .times. 10.sup.-8 MProduct of Example 15 5.01 .times. 10.sup.-8 MProduct of Example 16 1.00 .times. 10.sup.-7 MProduct of Example 17 1.31 .times. 10.sup.-8 MProduct of Example 18 3.16 .times. 10.sup.-8 MProduct of Example 19 1.00 .times. 10.sup.-8 MProduct of Example 20 1.00 .times. 10.sup.-7 MProduct of Example 21 1.00 .times. 10.sup.-7 MProduct of Example 22 1.82 .times. 10.sup.-8 MProduct of Example 23 1.00 .times. 10.sup.-7 MProduct of Example 24 1.00 .times. 10.sup.-8 MProduct of Example 25 4.57 .times. 10.sup.-8 MProduct of Example 26 3.71 .times. 10.sup.-9 MProduct of Example 27 3.98 .times. 10.sup.-9 MProduct of Example 28 1.31 .times. 10.sup.-8 MProduct of Example 29 1.81 .times. 10.sup.-8 MProduct of Example 30 2.34 .times. 10.sup.-9 MProduct of Example 31 1.77 .times. 10.sup.-8 MProduct of Example 32 1.58 .times. 10.sup.-8 MProduct of Example 33 6.30 .times. 10.sup.-9 MProduct of Example 34 1.31 .times. 10.sup.-8 MProduct of Example 35 5.75 .times. 10.sup.-9 MProduct of Example 36 3.16 .times. 10.sup.-9 MProduct of Example 37 1.00 .times. 10.sup.-8 MProduct of Example 38 2.51 .times. 10.sup.-8 MProduct of Example 39 2.69 .times. 10.sup.-9 MProduct of Example 40 2.23 .times. 10.sup.-9 MProduct of Example 41 .sup. 7.76 .times. 10.sup.-10 MProduct of Example 42 4.16 .times. 10.sup.-9 MProduct of Example 43 8.31 .times. 10.sup.-9 MProduct of Example 44 1.58 .times. 10.sup.-8 MProduct of Example 45 1.09 .times. 10.sup.-9 MProduct of Example 46 3.01 .times. 10.sup.-9 MProduct of Example 47 1.25 .times. 10.sup.-9 MProduct of Example 48 2.95 .times. 10.sup.-8 MProduct of Example 49 3.98 .times. 10.sup.-9 MProduct of Example 50 1.34 .times. 10.sup.-9 MProduct of Example 51 2.51 .times. 10.sup.-9 MProduct of Example 52 6.02 .times. 10.sup.-9 MProduct of Example 53 3.16 .times. 10.sup.-6 MProduct of Example 54 1.20 .times. 10.sup.-9 MProduct of Example 59 3.72 .times. 10.sup.-9 MProduct of Example 60 4.47 .times. 10.sup.-8 MProduct of Example 61 2.24 .times. 10.sup.-9 MProduct of Example 62 1.35 .times. 10.sup.-9 MProduct of Example 63 2.95 .times. 10.sup.-9 MProduct of Example 64 1.00 .times. 10.sup.-8 MProduct of Example 65 2.51 .times. 10.sup.-8 MProduct of Example 66 2.24 .times. 10.sup.-9 MProduct of Example 67 1.99 .times. 10.sup.-8 MProduct of Example 68 1.31 .times. 10.sup.-8 MProduct of Example 70 9.33 .times. 10.sup.-9 MProduct of Example 71 1.00 .times. 10.sup.-8 MProduct of Example 72 3.98 .times. 10.sup.-8 MProduct of Example 73 4.4 .times. 10.sup.-9 MProduct of Example 74 2.00 .times. 10.sup.-8 MProduct of Example 75 7.08 .times. 10.sup.-9 MProduct of Example 77 5.37 .times. 10.sup.-9 MProduct of Example 78 2.29 .times. 10.sup.-9 MProduct of Example 79 6.60 .times. 10.sup.-9 MProduct of Example 80 1.34 .times. 10.sup.-9 MProduct of Example 81 3.16 .times. 10.sup.-9 MProduct of Example 82 4.07 .times. 10.sup.-9 MProduct of Example 83 3.16 .times. 10.sup.-9 MProduct of Example 84 5.01 .times. 10.sup.-9 MProduct of Example 85 5.01 .times. 10.sup.-9 MProduct of Example 86 1.58 .times. 10.sup.-9 MProduct of Example 87 1.00 .times. 10.sup.-7 MProduct of Example 88 .sup. 1.26 .times. 10.sup.-10 MProduct of Example 89 .sup. 5.01 .times. 10.sup.-10 MProduct of Example 90B 1.00 .times. 10.sup.-8 MProduct of Example 91A 1.00 .times. 10.sup.-9 MProduct of Example 91B 2.5 .times. 10.sup.-9 M______________________________________

Number	Name	Date
4144343	Baldwin et al.	Mar 1979
4284634	Sato	Aug 1981
4430333	Campbell et al.	Feb 1984

Number	Date	Country
0031801	Jul 1981	EPX
0060674	Sep 1982	EPX
0089167	Sep 1983	EPX
2658183	Jul 1978	DEX
2740080	Mar 1979	DEX
2844595	Apr 1980	DEX
3022030	Dec 1981	DEX
55-47656	Apr 1980	JPX
1585978	Mar 1981	GBX

Dihydropyridines

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (1)

US Referenced Citations (3)

Foreign Referenced Citations (9)

Non-Patent Literature Citations (8)

Entry
Fossheim et al., CA 96:52141y.
Meyer et al., CA 95:143841x.
Deme et al., CA 96:68160x.
Wamhoff et al., CA 96:217781x.
Meyer et al., CA 88:120947c.
Kastron et al., CA 91:91466b.
Aritomi et al., CA 94:156797n.
Dainippon Pharmaceutical Co., CA 94:15570a.